Biopharmaceutical giant Biocon has appointed Mukesh Kamath, currently the Head of Business Finance R&D, as the Interim Chief Financial Officer (CFO) and Key Managerial Personnel. Kamath’s appointment took effect on June 11, 2024, and will continue until the board appoints a permanent CFO.
Kamath brings a wealth of experience to the role, having worked across all finance areas within the Biocon Group since he joined the company in 2004 as a Management Executive. His current responsibilities include overseeing Business Finance R&D, Indirect Taxation, Capital Expenditure (Capex), and other finance-related functions.
Before joining Biocon, Kamath held various roles at United Breweries, Infodesk Manipal, and Techsar Technologies. He is a qualified Chartered Accountant from the Institute of Chartered Accountants of India and holds a Bachelor of Commerce degree from Kuvempu University.
Biocon’s appointment of Kamath follows the resignation of the previous CFO, Indranil Sen, who stepped down in March 2024 to pursue other career opportunities. Sen had been with Biocon since April 2021, succeeding Anupam Jindal.